BioAge Labs (BIOA) director James Healy receives 22,000 stock options at $15.48

Rhea-AI Filing Summary

BioAge Labs, Inc. director James Healy received a grant of stock options tied to the company’s common stock. The award covers 22,000 options with an exercise price of $15.48 per share and expires on June 9, 2036.

According to the terms, the entire option award will vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, provided Healy continues to serve the company through the applicable vesting date. After this grant, he holds 22,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HEALY JAMES

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	22,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 22,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 22,000 options Exercise price: $15.48 per share Expiration date: June 9, 2036 +1 more

4 metrics

Options granted 22,000 options Stock Option (Right to Buy) grant to director

Exercise price $15.48 per share Stock option strike price for BioAge Labs common stock

Expiration date June 9, 2036 Option award expiration

Post-grant derivative holdings 22,000 derivative securities Total stock options held after this grant

Key Terms

Stock Option (Right to Buy), grant/award acquisition, Common Stock, annual meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of the Issuer's stockholders financial

"the date of the next annual meeting of the Issuer's stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEALY JAMES

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.48	06/10/2026		A		22,000		(1)	06/09/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Dov A. Goldstein as attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioAge Labs (BIOA) director James Healy report on this Form 4?

James Healy reported receiving a stock option grant for 22,000 shares of BioAge Labs common stock. These derivative securities give him the right to buy shares at a fixed exercise price, structured as part of his director compensation package.

How many BioAge Labs (BIOA) options did James Healy receive and at what price?

James Healy received 22,000 stock options with an exercise price of $15.48 per share. This means he can purchase BioAge Labs common stock at $15.48, regardless of future market price, once the options are vested and exercisable.

When do James Healy’s BioAge Labs (BIOA) stock options vest?

The entire option award vests on the earlier of the next BioAge Labs annual stockholder meeting or the one-year anniversary of the grant date. Vesting is conditioned on Healy’s continued service to the company through that vesting date.

What is the expiration date of James Healy’s BioAge Labs (BIOA) option grant?

The stock options granted to James Healy expire on June 9, 2036. After that date, any unexercised options will lapse, and he will no longer have the right to purchase BioAge Labs common stock under this specific award.

Is James Healy’s Form 4 for BioAge Labs (BIOA) a purchase or a grant?

James Healy’s Form 4 reflects a grant or award of derivative securities, not an open-market purchase. The transaction code is “A,” indicating a grant or other acquisition of stock options as part of his role with BioAge Labs.